Haematologica, Vol 92, Issue 4, 568-569 doi:10.3324/haematol.10797
Copyright © 2007 by Ferrata Storti Foundation
Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin’s lymphoma: results of a prematurely closed phase II study (NCT00148018)
Sven Trelle*,°,
Orhan Sezer#,
Ralph Naumann@,
Mathias Rummel^,
Ulrich Keller
,
Andreas Engert*,
Peter Borchmann*,
* Department I of Internal Medicine, University of Cologne, Germany
° Department of Social and Preventive Medicine, University of Berne, Switzerland;
# Department of Internal Medicine II, Charité Campus Mitte Berlin, Germany
@ Department of Internal Medicine I, Technical University Dresden, Germany
^ Department of Internal Medicine II, University of Frankfurt, Germany
Department of Internal Medicine III, Technical University Munich, Germany
Correspondence: Peter Borchmann, Klinik I für Innere Medizin, Klinikum der Universität zu Köln, 50924 Köln, Germany. Phone: international +41.221.478-5933. E-mail: peter.borchmann{at}uni-koeln.de
 |
ABSTRACT
|
|---|
We conducted a two-stage phase II study to investigate the activity of bortezomib and dexamethasone in patients with relapsed Hodgkin’s lymphoma. The study was prematurely closed after the first stage with twelve enrolled patients because no response was observed. A meta-analysis of all four available studies evaluating bortezomib in this population showed no activity of bortezomib (combined response rate: 0.03; 95%-CI: 0.01 to 0.12).
Key words: bortezomib, Hodgkin’s disease, lymphoma, phase II clinical trial, recurrence.
Hodgkin/Reed-Sternberg cells are known to be resistant to apoptosis due to over-expression of nuclear factor
B (NF-B).1 The proteasome inhibitor bortezomib is known to inhibit the activation of NF-B.2 Its activity has been shown in HL-derived cell lines.3 We therefore evaluated the anti-tumor activity of bortezomib in combination with dexamethasone in patients with relapsed Hodgkin’s lymphoma.
Ethical approval was sought in every participating institution before initiation of this phase II study. All participants gave written informed consent before entering the study. Patients must have had progressive, histologically proven Hodgkin’s lymphoma after at least one chemo- or radiotherapy. All patients were treated with 1.3 mg/m3 bortezomib intravenously and 20 mg dexamethasone orally on days 1, 4, 8, and 11 of a three-weekly cycle for up to eight cycles. A detailed schedule and dose modification scheme based on the package insert was employed if patients experienced toxicities. Patients were staged and restaged according to standard criteria before study treatment.4,5 Toxicities were assessed at each study visit according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. After every other cycle patients were clinically restaged and an interim staging with computed tomography of initially involved sites was performed after four cycles. Final treatment evaluation was performed 29 days after the last treatment cycle. Response to treatment was assessed and defined according to standard criteria.4,5
This study was a two-stage phase II study. The primary outcome was overall response rate (ORR; partial or complete responses). Sample size was calculated according to Simon’s optimal design. With type I error set at 0.1 to conclude the activity of an uninteresting regimen (ORR <5%) and type II error set at 0.1 implying the rejection of an active regimen (ORR >20%) it was necessary to recruit twelve patients in the first stage of the study. If one or more responses had been observed 25 additional patients would have been recruited. Secondary endpoints of the study were toxicity, event-free survival, duration of response, and treatment administration procedures. In order to facilitate interpretation of our study results, we performed a systematic review and meta-analysis of all prospective phase II studies of bortezomib reporting response data for at least one patient with Hodgkin’s lymphoma. We combined data on overall response using binomial regression analysis.
Between January 2005 and February 2006 a total of twelve patients were enrolled in the first stage of the study as specified in the protocol (Table 1). The median concentration of circulating proteasome was higher in study patients (n=8) compared to controls (431 ng/ml versus 210 ng/ml; p<0.001). All twelve patients were assessable for treatment administration and response. Eleven patients were assessable for toxicity.
Overall, 28 cycles were administered with a median of two cycles per patient (range: 2–8) (Table 1). The median received total dose was 10.4 mg/m2 (range: 8.3 –36.8 mg/m2) resulting in a median standardized received dose of 0.25 (range: 0.20–0.88). Three patients had at least one treatment delay, two had at least one dose modification, and three patients had both, treatment delay and dose modification, all because of toxicities. Two patients with stable disease, prematurely discontinued study treatment due to toxicities after two and three cycles, respectively. All of the other ten patients had progressive disease (overall response rate: 0.0; 95%-CI: 0.0 to 0.24). Nine of these prematurely discontinued study treatment after a median of two cycles (range: 2–5 cycles) and only one received all eight cycles (Table 1). Since no response was observed in the first twelve patients the study was stopped after the first stage. Eight patients experienced at least one toxicity greater than grade I requiring some dose modifications, treatment delays, or discontinuation (Table 1). We identified three other studies reporting response data for patients with Hodgkin’s lymphoma.6–8 Patients in all of these studies received the same dose of bortezomib within the same schedule as our study but without dexamethasone. Overall, results of all four studies agree in showing that bortezomib has no or only limited single-agent activity and this was confirmed by meta-analysis (Figure 1).
Laboratory studies with Hodgkin’s lymphoma derived cell cultures showed that bortezomib potentiates the activity of chemotherapy.9 Animal studies further indicate that the combination of an anti-CD30 antibody with bortezomib might be more promising than single-agent bortezomib.10 Further studies of bortezomib in Hodgkin’s lymphoma might therefore only be justified with combinations of bortezomib. However, the use of bortezomib combined with dexamethasone is not encouraged in patients with relapsed Hodgkin’s lymphoma.
|
Acknowledgements
|
|---|
we are indebted to Margret Platz for data management and study assistance and to all patients who participated in this study.
|
Footnotes
|
|---|
Funding: this study was supported by Johnson & Johnson Pharmaceutical Research and Development. The sponsor had no role in the design, management, analysis, and interpretation of the data or the decision to submit the manuscript. ST and PB had full access to all study data.
|
References
|
|---|
- Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, et al. High-level nuclear NF-B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996;87:4340-7.[Abstract/Free Full Text]
- Epinat JC, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/NF-B signal transduction pathway. Oncogene 1999;18:6896-909.[CrossRef][ISI][Medline]
- Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin’s disease cell lines is independent of inhibitor of nuclear factor-B mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004;10:3207-15.[Abstract/Free Full Text]
- Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.[Abstract/Free Full Text]
- Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6.[Abstract]
- Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 2006;107:1731-2.[Free Full Text]
- Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006;24:2105-12.[Abstract/Free Full Text]
- Blum KA, Johnson JL, Niedzwiecki D, Cannellos GP, Cheson BD, Bartlett NL. A phase II study of bortezomib in relapsed Hodgkin lymphoma: preliminary results of CALGB 50206. J Clin Oncol 2006;24:7576[Abstract].
- Georgakis GV, Li Y, Humphreys R, Andreeff M, O’Brien S, Younes M, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005;130:501-10.[CrossRef][ISI][Medline]
- Boll B, Hansen H, Heuck F, Reiners K, Borchmann P, Rothe A, et al. The fully human anti-CD30 antibody 5F11 activates NF-B and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood 2005;106:1839-42.[Abstract/Free Full Text]
This article has been cited by other articles:
|
|
|
|
 
J. H. Mendler, J. Kelly, S. Voci, D. Marquis, L. Rich, R. M. Rossi, S. H. Bernstein, C. T. Jordan, J. Liesveld, R. I. Fisher, et al.
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma
Ann. Onc.,
May 25, 2008;
(2008)
mdn365v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
TOP
ABSTRACT
Acknowledgements
